Key drivers include expanding Cabo’s indications and advancing Zanza pivotal trials. The Cabo franchise delivered strong growth, with Q4 U.S. net product revenues of $515 million, representing a ...

The adjustment comes after encouraging data from a Phase 1 study, STELLAR-001, which has bolstered confidence in the potential success of the company's Phase 3 study for its drug Zanza in a ...

At the ASCO GI conference, Exelixis shared Phase 1 clinical data for zanza in combination with atezolizumab for third-line and beyond colorectal cancer. The results were consistent with previous ...

The company highlighted ongoing developments in its Cabozantinib (CABO) and Zanza programs, while also addressing potential challenges. The conference showcased both optimism and cautious planning ...